Bortezomib treatment for severe refractory anti-NMDA receptor encephalitis.

ABSTRACT:

Objective

To evaluate the therapeutic potential of bortezomib, a proteasome inhibitor that target plasma cells, in order to revive stalled recovery in patients with anti-N-methyl-d-aspartate (NMDA) receptor encephalitis who remain bedridden even after aggressive immunotherapy.

Methods

We consecutively enrolled patients with anti-NMDA receptor encephalitis who remained bedridden after first-line immunotherapy (steroids and intravenous immunoglobulin), second-line immunotherapy (rituximab), and tocilizumab treatment, and treated them with subcutaneous bortezomib. Clinical response, functional recovery, and changes in antibody titer in the serum and cerebrospinal fluid were measured.

Results

Before the bortezomib treatment, the five patients with severe refractory

SUBMITTER: Shin YW 

PROVIDER: S-EPMC5945964 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature